Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary

PC. Taylor, A. Balsa, AB. Mongey, M. Filková, M. Chebbah, S. Le Clanche, LAW. Verhagen, T. Witte, D. Opris-Belinski, H. Marotte, J. Avouac

. 2024 ; 11 (6) : 1425-1435. [pub] 20241014

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002046

This commentary explores the potential cardiovascular (CV) benefits of combining methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid arthritis (RA). While European guidelines recommend MTX as first-line treatment, concerns about the CV risks associated with JAKis have emerged. This article reviews the existing literature to assess the role of concomitant MTX in reducing CV risk when used with JAKis. Clinical trials confirm the efficacy of JAKis in combination with MTX in terms of treatment outcomes in RA. However, the number of major adverse cardiovascular events (MACEs) reported is too low to draw conclusions on adverse CV outcomes. Indirect evidence does, however, suggest potential protective effects of MTX on CV outcomes, as several mechanisms may contribute to MTX's cardioprotective effects, including reduced inflammation, adenosine monophosphate-activated protein kinase (AMPK) activation, increased cholesterol efflux, and adenosine accumulation. These mechanisms and the available data may support the case for CV benefits of concomitant MTX when JAKis are used in the treatment of patients with RA, although further research is needed. In particular, the lipid paradox associated with RA highlights the complex relationship between RA treatments (MTX, JAKis, tumor necrosis factor (TNF) inhibitors, and interleukin (IL)-6 receptor inhibitors), inflammation, different lipid profiles, and CV risk. In the absence of contraindications and when MTX is tolerated, this commentary suggests the concomitant use of MTX and JAKis as a preferred option for optimizing CV protection in patients with RA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002046
003      
CZ-PrNML
005      
20250123102028.0
007      
ta
008      
250117s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40744-024-00721-x $2 doi
035    __
$a (PubMed)39397239
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Taylor, Peter C $u Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk
245    10
$a Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary / $c PC. Taylor, A. Balsa, AB. Mongey, M. Filková, M. Chebbah, S. Le Clanche, LAW. Verhagen, T. Witte, D. Opris-Belinski, H. Marotte, J. Avouac
520    9_
$a This commentary explores the potential cardiovascular (CV) benefits of combining methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid arthritis (RA). While European guidelines recommend MTX as first-line treatment, concerns about the CV risks associated with JAKis have emerged. This article reviews the existing literature to assess the role of concomitant MTX in reducing CV risk when used with JAKis. Clinical trials confirm the efficacy of JAKis in combination with MTX in terms of treatment outcomes in RA. However, the number of major adverse cardiovascular events (MACEs) reported is too low to draw conclusions on adverse CV outcomes. Indirect evidence does, however, suggest potential protective effects of MTX on CV outcomes, as several mechanisms may contribute to MTX's cardioprotective effects, including reduced inflammation, adenosine monophosphate-activated protein kinase (AMPK) activation, increased cholesterol efflux, and adenosine accumulation. These mechanisms and the available data may support the case for CV benefits of concomitant MTX when JAKis are used in the treatment of patients with RA, although further research is needed. In particular, the lipid paradox associated with RA highlights the complex relationship between RA treatments (MTX, JAKis, tumor necrosis factor (TNF) inhibitors, and interleukin (IL)-6 receptor inhibitors), inflammation, different lipid profiles, and CV risk. In the absence of contraindications and when MTX is tolerated, this commentary suggests the concomitant use of MTX and JAKis as a preferred option for optimizing CV protection in patients with RA.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Balsa, Alejandro $u Rheumatology Unit, University Hospital La Paz, Institute for Health Research-IdiPAZ, Universidad Autonoma de Madrid, 28046, Madrid, Spain
700    1_
$a Mongey, Anne-Barbara $u Department of Rheumatology, School of Medicine and Medical Sciences, St. Vincent's University Hospital, University College Dublin, Dublin 4, Ireland
700    1_
$a Filková, Mária $u Institute of Rheumatology, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Chebbah, Myriam $u Département Affaires Médicales, Public Health Expertise, 10 Boulevard de Sébastopol, 75004, Paris, France
700    1_
$a Le Clanche, Solenn $u Département Affaires Médicales, Public Health Expertise, 10 Boulevard de Sébastopol, 75004, Paris, France
700    1_
$a Verhagen, Linda A W $u Nordic Pharma B.V., Siriusdreef 41, 2132 WT, Hoofddorp, The Netherlands
700    1_
$a Witte, Torsten $u Klinik Für Rheumatologie und Immunologie, Medizinische Hochschule Hannover Carl-Neuberg-Str. 1, 30625, Hannover, Germany
700    1_
$a Opris-Belinski, Daniela $u Internal Medicine and Rheumatology, Sfanta Maria Hospital, Carol Davila University of Medicine, Bucharest, Romania
700    1_
$a Marotte, Hubert $u Université Jean Monnet, Service de Rhumatologie, CHU Saint-Etienne, Mines Saint-Etienne, INSERM U1059, Saint-Etienne, France
700    1_
$a Avouac, Jérôme $u Service de Rhumatologie, Hôpital Cochin, AP-HP Centre-Université Paris Cité, 75014, Paris, France
773    0_
$w MED00207609 $t Rheumatology and therapy $x 2198-6576 $g Roč. 11, č. 6 (2024), s. 1425-1435
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39397239 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123102022 $b ABA008
999    __
$a ok $b bmc $g 2254461 $s 1238049
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 11 $c 6 $d 1425-1435 $e 20241014 $i 2198-6576 $m Rheumatology and therapy $n Rheumatol Ther $x MED00207609
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace